Alzheimer's Matters Blog

Top 5 Alzheimer's Advances in 2017

ADDF Impact

Top Five Alzheimer’s Advances in 2017

Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.

Developing Drugs

Alzheimer’s Biomarkers, Explained

Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.  

Dr. Roberta Diaz Brinton

Developing Drugs

Closing in on a Cure: Dr. Roberta Diaz Brinton and Allopregnanolone

With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.

CTAD 2017 Conference

ADDF Impact

CTAD Conference Highlights Our Funded Research

This Wednesday marks the beginning of National Alzheimer's Disease Awareness Month and the 10th Clinical Trials on Alzheimer's Disease conference, which features a record amount of research we have supported.

Combination Therapy

Developing Drugs

Combination Therapy: The Right Approach for Alzheimer’s

Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.

Howard Fillit and D. Martin Watterson

ADDF Impact

Driving Innovation in Alzheimer’s Therapies

At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.